Labeling for Several HCV Drugs Updated With New Drug Interactions - Hallo friend NEWS AN INSPIRATION, In the article you read this time with the title Labeling for Several HCV Drugs Updated With New Drug Interactions, we have prepared well for this article you read and download the information therein. hopefully fill posts Article ECONOMY, Article HEALTH, Article POLITICS, Article SPORTS, Article TRAVELING, Article UPDATE, we write can understand. Well, happy reading.

Titre : Labeling for Several HCV Drugs Updated With New Drug Interactions
link : Labeling for Several HCV Drugs Updated With New Drug Interactions

Labeling for Several HCV Drugs Updated With New Drug Interactions

Review

Labeling for Several HCV Drugs Updated With New Drug Interactions
Specifically, the prescribing information for Viekira Pak (ombitasvir, paritaprevir, ritonavir, with dasabuvir; AbbVie), Viekira XR (dasabuvir, ombitasvir, paritaprevir, ritonavir; AbbVie), Technivie (ombitasvir, paritaprevir, ritonavir; AbbVie), Sovaldi (sofosbuvir; Gilead), Harvoni (ledipasvir, sofosbuvir; Gilead), Epclusa (sofosbuvir, velpatasvir; Gilead), Vosevi (sofosbuvir, velpatasvir, voxilaprevir; Gilead), Olysio (simeprevir; Janssen), Daklinza (daclatasvir; Bristol-Myers Squibb), and Zepatier (elbasvir, grazoprevir; Merck) has been updated to include information pertaining to changes in International Normalized Ratio (INR) values in patients receiving warfarin. Fluctuations in INR values may occur in patients receiving warfarin concomitant with HCV treatment. 

Read more..... http://ift.tt/2hx0ctu

Thus articles Labeling for Several HCV Drugs Updated With New Drug Interactions

that is all articles Labeling for Several HCV Drugs Updated With New Drug Interactions This time, hopefully can provide benefits to you all. Okay, see you in another article post.

You are now reading the article Labeling for Several HCV Drugs Updated With New Drug Interactions the link address https://newsaninpiration.blogspot.com/2017/11/labeling-for-several-hcv-drugs-updated.html

Tweet

Subscribe to receive free email updates: